Paclitaxel News and Research

RSS
Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.
HKBU experts develop new generation of smart anti-cancer drug molecules

HKBU experts develop new generation of smart anti-cancer drug molecules

New first line combination therapy shows promising results in patients with advanced NSCLC

New first line combination therapy shows promising results in patients with advanced NSCLC

Researchers find potential approach to prevent peripheral neuropathy

Researchers find potential approach to prevent peripheral neuropathy

FDA approved drug found to have anti-cancer activity against previously unknown targets

FDA approved drug found to have anti-cancer activity against previously unknown targets

Drug approved to treat parasitic infections also exerts anti-tumor effect on EOC cells

Drug approved to treat parasitic infections also exerts anti-tumor effect on EOC cells

FDA grants approval for new biosimilar to treat multiple types of cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

MTI awards $25,000 grant to MDI Biological Laboratory scientist for peripheral neuropathy research

MTI awards $25,000 grant to MDI Biological Laboratory scientist for peripheral neuropathy research

Study finds potential preventive for chemotherapy-induced peripheral neuropathy

Study finds potential preventive for chemotherapy-induced peripheral neuropathy

Study: Chemoradiation should remain standard treatment for locally advanced cervical cancer

Study: Chemoradiation should remain standard treatment for locally advanced cervical cancer

Trial confirms standard three-week dosing of chemotherapy as first line treatment in ovarian cancer

Trial confirms standard three-week dosing of chemotherapy as first line treatment in ovarian cancer

UC San Diego researchers receive $18.2 million grant for B cell cancer clinical trial

UC San Diego researchers receive $18.2 million grant for B cell cancer clinical trial

Researchers find clues to how chemotherapy drug fuels cancer spread from the breast to lungs

Researchers find clues to how chemotherapy drug fuels cancer spread from the breast to lungs

Two cell types partner to protect pancreatic tumors from immune attack

Two cell types partner to protect pancreatic tumors from immune attack

Immunotherapy combination offers new hope for women with early stage triple negative breast cancer

Immunotherapy combination offers new hope for women with early stage triple negative breast cancer

Rice University scientists develop and evaluate analogs of potent cancer fighters

Rice University scientists develop and evaluate analogs of potent cancer fighters

New study offers insight into how to improve chemotherapy strategies for ovarian cancer

New study offers insight into how to improve chemotherapy strategies for ovarian cancer

Researchers use mathematical modeling to find effective chemotherapy treatments for cancer patients

Researchers use mathematical modeling to find effective chemotherapy treatments for cancer patients

MDI Biological Laboratory investigator awarded NIH grant for research on peripheral neuropathy

MDI Biological Laboratory investigator awarded NIH grant for research on peripheral neuropathy

Combination of TTFields with standard therapies may improve survival in pancreatic cancer patients

Combination of TTFields with standard therapies may improve survival in pancreatic cancer patients

Phase 2 study shows encouraging results for TTFields therapy in treating recurrent ovarian cancer

Phase 2 study shows encouraging results for TTFields therapy in treating recurrent ovarian cancer